Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
Author:
Affiliation:
1. Department of Life Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy
Funder
Associazione Italiana per la Ricerca sul Cancro
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00438
Reference124 articles.
1. The Web site of the National Cancer Institute.http://www.cancer.gov(accessed December 22, 2015) .
2. Protein kinases — the major drug targets of the twenty-first century?
3. Mechanisms of specificity in protein phosphorylation
4. The protein kinase activity modulation sites:
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Myelofibrosis: In Search for BETter Targeted Therapies;Journal of Clinical Oncology;2023-11-10
2. Bromodomain inhibitors and therapeutic applications;Current Opinion in Chemical Biology;2023-08
3. LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies;Biomedical Chromatography;2023-04-27
4. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications;Molecules;2023-03-29
5. MDM2 antagonists promote CRISPR/Cas9-mediated precise genome editing in sheep primary cells;Molecular Therapy - Nucleic Acids;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3